Evaluation of Biochemical Parameters in Type 2 Diabetes Mellitus Patients with Non-Alcoholic Fatty Liver Disease at a Tertiary Care Hospital in Bhopal
DOI:
https://doi.org/10.52783/jns.v14.2783Keywords:
Type 2 diabetes mellitus, Non-alcoholic fatty liver disease, Total cholesterol, Triglycerides, Low-density lipoprotein, High-density lipoprotein, HbA1cAbstract
Background: Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease worldwide and can progress to fibrosis and cirrhosis. NAFLD is increasingly prevalent, particularly in individuals with central obesity, type 2 diabetes mellitus (T2DM), dyslipidemia, and metabolic syndrome.
Objective: To assess biochemical parameters in patients with T2DM and NAFLD at a tertiary care hospital in Bhopal.
Methods: This study was conducted in the Department of Biochemistry at L.N. Medical College and J.K. Hospital, involving 70 subjects diagnosed with T2DM and NAFLD. NAFLD severity was classified into three grades (1–3) based on abdominal ultrasonography findings. Biochemical parameters analyzed included HbA1c, serum cholesterol, triglycerides, low-density lipoprotein (LDL), and high-density lipoprotein (HDL).
Results: Among 70 participants, those with NAFLD Grade 3 had the highest total cholesterol levels (Mean TC = 266 mg/dL). Grade 3 participants (n=17) exhibited elevated triglyceride levels (Mean TG = 246 mg/dL), while Grade 2 participants (n=25) had increased LDL levels. Grade 1 participants had the lowest HDL levels (Mean HDL = 35 mg/dL). Dyslipidemia, characterized by elevated triglycerides or LDL with reduced HDL, was the most common abnormality. Total cholesterol, LDL, and HDL levels were significantly associated with NAFLD severity, whereas triglyceride variations across NAFLD grades were not statistically significant.
Conclusion: This study highlights the importance of recognizing fatty liver as a component of metabolic syndrome in individuals with diabetes mellitus. Regular monitoring of lipid profiles in T2DM patients with NAFLD is essential for early intervention and management.
Downloads
Metrics
References
El-Kassas M, Cabezas J, Coz PI, Zheng MH, Arab JP, Awad A. Nonalcoholic fatty liver disease: current global burden. Semin Liver Dis. 2022;42(3):401-12.
Frank J, Kisters K, Stirban OA, Obeid R, Lorkowski S, Wallert M, et al. The role of biofactors in the prevention and treatment of age-related diseases. Biofactors. 2021;47(4):522-50.
Polyzos SA, Kang ES, Tsochatzis EA, Kechagias S, Ekstedt M, Xanthakos S, et al. Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. Metabolism. 2020;113:154413.
Pais R, Barritt AS, Calmus Y, Scatton O, Runge T, Lebray P, et al. NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol. 2016;65:1245-57.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84.
Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment PharmacolTher. 2011;34:274-85.
Sherif ZA, Saeed A, Ghavimi S, Nouraie SM, Laiyemo AO, Brim H, et al. Global epidemiology of nonalcoholic fatty liver disease and perspectives on US minority populations. Dig Dis Sci. 2016;61:1214-25.
Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. TranslGastroenterolHepatol. 2020;5:16.
De A, Duseja A. Nonalcoholic fatty liver disease: Indian perspective. Clin Liver Dis (Hoboken). 2021;18:158-63.
Shalimar, Elhence A, Bansal B, Gupta H, Anand A, Singh TP, et al. Prevalence of non-alcoholic fatty liver disease in India: A systematic review and meta-analysis. J ClinExpHepatol. 2022;12:818-29.
Cusi K, GodinezLeiva E. Cardiovascular risk in patients with nonalcoholic fatty liver disease: looking at the liver to shield the heart. CurrOpinLipidol. 2020;31:364-6.
Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501,022 adult individuals. Gut. 2021;70:962-9.
Stefan N, Cusi K. A global view of the interplay between nonalcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022;10:284-96.
Bae JH, Han KD, Ko SH, et al. Diabetes fact sheet in Korea 2021. Diabetes Metab J. 2022;46:417-26.
ElSayed NA, Aleppo G, Aroda VR, et al. Cardiovascular disease and risk management: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S158-90.
Lee BW, Lee YH, Park CY, et al. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: a position statement of the Fatty Liver Research Group of the Korean Diabetes Association. Diabetes Metab J. 2020;44:382-401.
Caussy C, Aubin A, Loomba R. The relationship between type 2 diabetes, NAFLD, and cardiovascular risk. CurrDiab Rep. 2021;21:15.
Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care. 2007;30:2119-21.
Vanjiappan S, Hamide A, Ananthakrishnan R, Periyasamy SG, Mehalingam V. Nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and its association with cardiovascular disease. Diabetes MetabSyndr. 2018;12:479-82.
Zhou YY, Zhou XD, Wu SJ, et al. Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis. Eur J GastroenterolHepatol. 2018;30:631-6.
Targher G, Bertolini L, Poli F, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes. 2005;54:3541-6.
Wild SH, Walker JJ, Morling JR, et al. Cardiovascular disease, cancer, and mortality among people with type 2 diabetes and alcoholic or nonalcoholic fatty liver disease hospital admission. Diabetes Care. 2018;41:341-7.
Hu X, Yu W. First-degree family history of diabetes is associated with nonalcoholic fatty liver disease independent of glucose metabolic status. J Diabetes Complications. 2022;36(1):108083.
Suryawanshi NP, Bhutey AK, Nagdeote AN, Jadhav AA, Manoorkar GS. Study of lipid peroxide and lipid profile in diabetes mellitus. Indian J ClinBiochem. 2006;21(1):126-30.
Liu YL, Reeves HL, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun. 2014;5:4309.
Tatsta M, Ono M, Kimura S, et al. HbA1c of 5.8% or higher as the most useful indicator for recommendation of ultrasonography to detect nonalcoholic fatty liver disease.
Oikonomou D, Ioannou GN, Weiss NS, Boyko EJ, Mozaffarian D, Lee SP. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology. 2006;43(5):1145-51.
Puneem US, Nagasubramaniam VR, Sindgi VM, et al. Health-related quality of life and its determinants among South Indian type 2 diabetes patients with and without nonalcoholic fatty liver disease. Egypt Liver J. 2023;13:57.
Dharmalingam M. Nonalcoholic fatty liver disease and type 2 diabetes mellitus. Indian J EndocrinolMetab. 2018;22(3):421-8.
Xia MF, Bian H, Gao X. NAFLD and diabetes: two sides of the same coin? Rationale for gene-based personalized NAFLD treatment. Front Pharmacol. 2019;10:877.
Bhatt KN. Prevalence of nonalcoholic fatty liver disease in type 2 diabetes mellitus and its relationship with insulin resistance in South Gujarat region. J Mahatma Gandhi Inst Med Sci. 2017;22(1):8.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
